Cargando…
In vivo labeling reveals continuous trafficking of TCF-1(+) T cells between tumor and lymphoid tissue
Improving the efficacy of immune checkpoint therapies will require a better understanding of how immune cells are recruited and sustained in tumors. Here, we used the photoconversion of the tumor immune cell compartment to identify newly entering lymphocytes, determine how they change over time, and...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048291/ https://www.ncbi.nlm.nih.gov/pubmed/35472220 http://dx.doi.org/10.1084/jem.20210749 |
_version_ | 1784695900803694592 |
---|---|
author | Li, Zhi Tuong, Zewen K. Dean, Isaac Willis, Claire Gaspal, Fabrina Fiancette, Rémi Idris, Suaad Kennedy, Bethany Ferdinand, John R. Peñalver, Ana Cabantous, Mia Murtuza Baker, Syed Fry, Jeremy W. Carlesso, Gianluca Hammond, Scott A. Dovedi, Simon J. Hepworth, Matthew R. Clatworthy, Menna R. Withers, David R. |
author_facet | Li, Zhi Tuong, Zewen K. Dean, Isaac Willis, Claire Gaspal, Fabrina Fiancette, Rémi Idris, Suaad Kennedy, Bethany Ferdinand, John R. Peñalver, Ana Cabantous, Mia Murtuza Baker, Syed Fry, Jeremy W. Carlesso, Gianluca Hammond, Scott A. Dovedi, Simon J. Hepworth, Matthew R. Clatworthy, Menna R. Withers, David R. |
author_sort | Li, Zhi |
collection | PubMed |
description | Improving the efficacy of immune checkpoint therapies will require a better understanding of how immune cells are recruited and sustained in tumors. Here, we used the photoconversion of the tumor immune cell compartment to identify newly entering lymphocytes, determine how they change over time, and investigate their egress from the tumor. Combining single-cell transcriptomics and flow cytometry, we found that while a diverse mix of CD8 T cell subsets enter the tumor, all CD8 T cells retained within this environment for more than 72 h developed an exhausted phenotype, revealing the rapid establishment of this program. Rather than forming tumor-resident populations, non-effector subsets, which express TCF-1 and include memory and stem-like cells, were continuously recruited into the tumor, but this recruitment was balanced by concurrent egress to the tumor-draining lymph node. Thus, the TCF-1(+) CD8 T cell niche in tumors is highly dynamic, with the circulation of cells between the tumor and peripheral lymphoid tissue to bridge systemic and intratumoral responses. |
format | Online Article Text |
id | pubmed-9048291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-90482912022-05-16 In vivo labeling reveals continuous trafficking of TCF-1(+) T cells between tumor and lymphoid tissue Li, Zhi Tuong, Zewen K. Dean, Isaac Willis, Claire Gaspal, Fabrina Fiancette, Rémi Idris, Suaad Kennedy, Bethany Ferdinand, John R. Peñalver, Ana Cabantous, Mia Murtuza Baker, Syed Fry, Jeremy W. Carlesso, Gianluca Hammond, Scott A. Dovedi, Simon J. Hepworth, Matthew R. Clatworthy, Menna R. Withers, David R. J Exp Med Article Improving the efficacy of immune checkpoint therapies will require a better understanding of how immune cells are recruited and sustained in tumors. Here, we used the photoconversion of the tumor immune cell compartment to identify newly entering lymphocytes, determine how they change over time, and investigate their egress from the tumor. Combining single-cell transcriptomics and flow cytometry, we found that while a diverse mix of CD8 T cell subsets enter the tumor, all CD8 T cells retained within this environment for more than 72 h developed an exhausted phenotype, revealing the rapid establishment of this program. Rather than forming tumor-resident populations, non-effector subsets, which express TCF-1 and include memory and stem-like cells, were continuously recruited into the tumor, but this recruitment was balanced by concurrent egress to the tumor-draining lymph node. Thus, the TCF-1(+) CD8 T cell niche in tumors is highly dynamic, with the circulation of cells between the tumor and peripheral lymphoid tissue to bridge systemic and intratumoral responses. Rockefeller University Press 2022-04-26 /pmc/articles/PMC9048291/ /pubmed/35472220 http://dx.doi.org/10.1084/jem.20210749 Text en © 2022 Li et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Zhi Tuong, Zewen K. Dean, Isaac Willis, Claire Gaspal, Fabrina Fiancette, Rémi Idris, Suaad Kennedy, Bethany Ferdinand, John R. Peñalver, Ana Cabantous, Mia Murtuza Baker, Syed Fry, Jeremy W. Carlesso, Gianluca Hammond, Scott A. Dovedi, Simon J. Hepworth, Matthew R. Clatworthy, Menna R. Withers, David R. In vivo labeling reveals continuous trafficking of TCF-1(+) T cells between tumor and lymphoid tissue |
title | In vivo labeling reveals continuous trafficking of TCF-1(+) T cells between tumor and lymphoid tissue |
title_full | In vivo labeling reveals continuous trafficking of TCF-1(+) T cells between tumor and lymphoid tissue |
title_fullStr | In vivo labeling reveals continuous trafficking of TCF-1(+) T cells between tumor and lymphoid tissue |
title_full_unstemmed | In vivo labeling reveals continuous trafficking of TCF-1(+) T cells between tumor and lymphoid tissue |
title_short | In vivo labeling reveals continuous trafficking of TCF-1(+) T cells between tumor and lymphoid tissue |
title_sort | in vivo labeling reveals continuous trafficking of tcf-1(+) t cells between tumor and lymphoid tissue |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048291/ https://www.ncbi.nlm.nih.gov/pubmed/35472220 http://dx.doi.org/10.1084/jem.20210749 |
work_keys_str_mv | AT lizhi invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT tuongzewenk invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT deanisaac invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT willisclaire invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT gaspalfabrina invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT fiancetteremi invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT idrissuaad invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT kennedybethany invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT ferdinandjohnr invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT penalverana invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT cabantousmia invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT murtuzabakersyed invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT fryjeremyw invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT carlessogianluca invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT hammondscotta invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT dovedisimonj invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT hepworthmatthewr invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT clatworthymennar invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue AT withersdavidr invivolabelingrevealscontinuoustraffickingoftcf1tcellsbetweentumorandlymphoidtissue |